Page 66 - Haematologica3

R. Bottega et al.
14. Nicchia E, Greco C, De Rocco D, et al.
Identification of point mutations and large intragenic deletions in Fanconi anemia using next-generation sequencing technolo- gy. Mol Genet Genomic Med. 2015; 3(6):500-512.
15. Antonio Casado J, Callén E, Jacome A, et al. A comprehensive strategy for the subtyp- ing of patients with Fanconi anaemia: con- clusions from the Spanish Fanconi Anemia Research Network. J Med Genet. 2007; 44(4):241-249.
16. Hanenberg H, Batish SD, Pollok KE, et al. Phenotypic correction of primary Fanconi anemia T cells with retroviral vectors as a diagnostic tool. Exp Hematol. 2002; 30(5):410-420.
17. Molina B, Marchetti F, Gómez L, et al. Hydroxyurea induces chromosomal dam- age in G2 and enhances the clastogenic effect of mitomycin C in Fanconi anemia cells. Environ Mol Mutagen. 2015; 56(5):457-467.
18. Savino M, Borriello A, D'Apolito M, et al. Spectrum of FANCA mutations in Italian Fanconi anemia patients: identification of six novel alleles and phenotypic characteri- zation of the S858R variant. Hum Mutat. 2003;22(4):338-339.
19. Columbaro M, Ravera S, Capanni C, et al. Treatment of FANCA cells with resveratrol and N-acetylcysteine: a comparative study. PLoS One. 2014;9(7):e104857.
20. Ravera S, Dufour C, Cesaro S, et al. Evaluation of energy metabolism and calci- um homeostasis in cells affected by Shwachman-Diamond syndrome. Sci Rep. 2016;6:25441.
21. Hinkle PC. P/O ratios of mitochondrial oxidative phosphorylation. Biochim Biophys Acta. 2005;1706(1-2):1-11.
22. Easton DF, Deffenbaugh AM, Pruss D, et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical sig- nificance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet. 2007;81(5):873-883.
23. Karras GI, Yi S, Sahni N, et al. HSP90 Shapes the Consequences of Human Genetic Variation. Cell. 2017;168(5):856- 866.e812.
24. Castella M, Pujol R, Callén E, et al. Origin, functional role, and clinical impact of Fanconi anemia FANCA mutations. Blood. 2011;117(14):3759-3769.
25. Tipping AJ, Pearson T, Morgan NV, et al. Molecular and genealogical evidence for a founder effect in Fanconi anemia families of the Afrikaner population of South Africa. Proc Natl Acad Sci USA. 2001;98(10):5734-5739.
26. Kutler DI, Auerbach AD. Fanconi anemia in Ashkenazi Jews. Fam Cancer. 2004;3(3- 4):241-248.
27. Savino M, Ianzano L, Strippoli P, et al. Mutations of the Fanconi anemia group A
gene (FAA) in Italian patients. Am J Hum
Genet. 1997;61(6):1246-1253.
28. MacVicar TD, Lane JD. Impaired OMA1-
dependent cleavage of OPA1 and reduced DRP1 fission activity combine to prevent mitophagy in cells that are dependent on oxidative phosphorylation. J Cell Sci. 2014; 127(Pt 10):2313-2325.
29. Kalb R, Neveling K, Hoehn H, et al. Hypomorphic mutations in the gene encoding a key Fanconi anemia protein, FANCD2, sustain a significant group of FA- D2 patients with severe phenotype. Am J Hum Genet. 2007;80(5):895-910.
30. Yamashita T, Wu N, Kupfer G, et al. Clinical variability of Fanconi anemia (type C) results from expression of an amino ter- minal truncated Fanconi anemia comple- mentation group C polypeptide with par- tial activity. Blood. 1996;87(10):4424-4432.
31. MacMillan ML, DeFor TE, Young JA, et al. Alternative donor hematopoietic cell trans- plantation for Fanconi anemia. Blood. 2015;125(24):3798-3804.
32. Lo Ten Foe JR, Kwee ML, Rooimans MA, et al. Somatic mosaicism in Fanconi anemia: molecular basis and clinical significance. Eur J Hum Genet. 1997;5(3):137-148.
33. Du W, Adam Z, Rani R, Zhang X, Pang Q. Oxidative stress in Fanconi anemia hematopoiesis and disease progression. Antioxid Redox Signal. 2008;10(11):1909- 1921.
426
haematologica | 2018; 103(3)